Clinical reviewPremature ovarian failure
References (28)
- et al.
A controlled study of Danazol for the treatment of karyotypically normal spontaneous premature ovarian failure
Fertil Steril
(1994) - et al.
- et al.
Incidence of premature ovarian failure
Obstet Gynaecol
(1986) - et al.
The significance of FSH elevation in young women with disorders of ovulation
Br Med J
(1980) - et al.
Familial premature ovarian failure due to an interstitial deletion of the long arm of the X-chromosome
N Engl J Med
(1987) - et al.
Molecular and cytogenetic studies of an X autosome translocation in a patient with premature ovarian failure and review of the literature
Am J Med Genet
(1994) - et al.
- et al.
Organ-specific autoimmunity in patients with premature ovarian failure
J Endocrinol Invest
(1993) - et al.
Autoimmune disease of the adrenal cortex, pituitary parathyroid glands and gastric mucosa
J Intern Med
(1993) - et al.
Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. (APECED) in a series of 68 patients
N Engl J Med
(1990)
What do we really know about autoantibody abnormalities and reproductive failure: a critical review
Autoimmunity
Identification of the main gonadal autoantigens in patients with adrenal insufficiency and associated ovarian failure
J Clin Endocrinol Metab
Editorial. Adrenal and gonadal autoimmune disease
J Clin Endocrinol Metab
The use of human recombinant gonadotrophin receptors to search for immunoglobulin G-mediated premature ovarian failure
J Clin Endocrinol Metab
Cited by (40)
Premature ovarian insufficiency and autoimmune diseases
2019, Best Practice and Research: Clinical Obstetrics and GynaecologyCitation Excerpt :Ovarian function may return after regression of the autoimmune status and control of coexistent endocrine disease. After confirming the diagnosis of POI and assessment of ovarian reserve, including endocrine and ultrasonography markers for evaluation of ovarian volume and follicular pool, there is an urgent need to determine the optimal therapeutic hormonal regimens, in terms of both immediate menopausal symptom relief and protection against the long-term sequelae of estrogen deficiency, such as osteoporosis [42,88,89]. In patients with POI, estrogen is used to overcome the effects of estrogen deficiency and to encourage recovery of ovarian function by restoration of receptor sensitivity to gonadotropins with a salutary effect on folliculogenesis and conception [47,90,91].
An immunological insight into premature ovarian failure (POF)
2010, Autoimmunity ReviewsCitation Excerpt :The recovery of ovarian function may occur after regression of the autoimmune status and control of coexistent endocrine disease. After confirming diagnosis of POF and assessment of ovarian reserve, including endocrine and ultrasonography markers for evaluation of ovarian volume and follicular pool, the urgent need to determine the optimum therapeutic hormonal regimens is required, both in terms of immediate menopausal symptoms relief and also for the protection against the long-term sequelae of estrogen deficiency, such as osteoporosis [29–32]. Although ovarian biopsy is gold standard for detecting autoimmune cause of immune ovarian destruction, it is questionable whether it accurately represents the follicular density of the whole ovary, particularly in idiopathic POF, characterized with variable degree of ovarian function preservation [11,33].
Familial premature ovarian failure in female premutated carriers of fragile X syndrome: A case report and literature review
2006, Taiwanese Journal of Obstetrics and GynecologyOophoritis
2006, The Autoimmune Diseases, Fourth EditionDiagnosis and management of amenorrhea
2002, Clinics in Family Practice